BioSpace News Archive

HistoSonics, (www.histosonics.com), the developer and manufacturer of a non-invasive platform and novel sonic beam therapy called histotripsy, announced today that the U.S. Food and Drug Administration (FDA) has granted the company Breakthrough Device Designation for its new therapy platform.

Nanjing Bioheng Biotech Co., Ltd, announced that Professor Carl June, an authoritative cancer immunologist and “Pioneer of Chimeric Antigen Receptor T cells,” officially joined the Bioheng scientific advisory board and acted as chairman.

SciSparc Ltd. (OTCQB: SPRCF), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the “Company”), today announced the publication of a manuscript that teaches the uses of its proprietary drug candidate SCI-110 for Tourette Syndrome (TS).

Cannabics Pharmaceuticals Inc. announced today that it has filed 2 new Provisional Patent applications on Compositions and Methods for treating cancer, including colorectal cancer and early intervention therapy for colorectal cancer patients.

Enveda Biosciences announced today the appointment of a new Chief Platform Officer (CPO), August Allen .

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced it will report its third quarter 2021 financial results and operational highlights on Thursday, November 4, 2021, following the close of U.S. financial markets.

bluebird bio, Inc. (NASDAQ: BLUE) today announced that October 19, 2021 has been set as the record date for the dividend of shares of common stock of 2seventy to be distributed to bluebird stockholders in order to effect the separation of bluebird bio and 2seventy bio, Inc. into two independent, publicly traded companies.

Charles River Laboratories International, Inc. (NYSE: CRL) and ATEM Structural Discovery (ATEM) today announced the formation of a strategic partnership to provide clients access to ATEM’s cryo-electron microscopy (cryo-EM) service solutions.

XVIVO is setting new standards in heart transplantation. In an ongoing clinical trial in Australia and New Zealand, a donor heart was preserved using Non Ischemic Heart Preservation technology for 7 hours and 18 minutes before successful transplantation into a 55-year-old man.

SPR Therapeutics announced today it has raised $37 million in an oversubscribed Series D growth equity financing.